Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 1/20 | 0.66 |
| ▸ | KRAS | P01116 | 1/20 | 0.66 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 5/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21207104 | 1.00 | HRAS (0.66) | HRASKRASBRD4NAMPTCD274 | |
| SCHEMBL29066259 | 0.93 | HRAS (0.62) | HRASKRASBRD4CD274PDCD1 | |
| SCHEMBL21201481 | 0.92 | HRAS (0.57) | HRASKRASBRD4NAMPTCD274 | |
| SCHEMBL24329998 | 0.88 | HRAS (0.68) | HRASKRASBRD4NAMPTCD274 | |
| SCHEMBL29582873 | 0.88 | HRAS (0.68) | HRASKRASBRD4NAMPTCD274 | |
| SCHEMBL21207018 | 0.84 | HRAS (0.58) | HRASKRASNAMPTCD274PDCD1 | |
| SCHEMBL30222551 | 0.84 | HRAS (0.58) | HRASKRASNAMPTCD274PDCD1 | |
| SCHEMBL21207083 | 0.84 | HRAS (0.74) | HRASKRASCD274PDCD1PDCD1LG2 | |
| SCHEMBL30913802 | 0.84 | HRAS (0.74) | HRASKRASCD274PDCD1PDCD1LG2 | |
| SCHEMBL21198782 | 0.84 | HRAS (0.74) | HRASKRASCD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | HRAS 3/4885KRAS 1/4885BRD4 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.